Background Prostate cancer screening incurs a high risk of overdiagnosis and
overtreatment. An organized and age‐targeted screening strategy may reduce the …

BACKGROUND Prostate‐specific antigen (PSA) screening and concomitant treatment can
be implemented in several ways. The authors investigated how the net benefit of PSA …

Background: The results of the European Randomized Study of Screening for Prostate
Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality …

While the benefit of prostate‐specific antigen (PSA) based screening is uncertain, a
significant proportion of screen‐detected cases is overdiagnosed. In order to make …

Background There is ongoing debate about the harms and benefits of a national prostate
cancer screening programme. Several model-based cost-effectiveness analyses have been …

Background Multiple guidelines seek to alter rates of prostate-specific antigen (PSA)-based
prostate cancer screening. The costs borne by payers associated with PSA-based screening …

Prostate‐specific antigen (PSA) screening for prostate cancer may reduce mortality, but it
incurs considerable risk of over diagnosis and potential harm to quality of life. Our objective …

Chinese translation Background: The US Preventive Services Task Force recently
concluded that the harms of existing prostate-specific antigen (PSA) screening strategies …

Importance Prostate-specific antigen (PSA) screening for prostate cancer is controversial.
Experts have suggested more personalized or more conservative strategies to improve …

Background After 11 years of follow-up, the European Randomized Study of Screening for
Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men …